Estimated Timeline. The Customer’s project will be scheduled with the appropriate project manager and engineering resources upon contract signing. TNL will provide Customer an estimated project timeline within (1) one week after contract signing. Timeline dates may vary depending on Customer configuration and customization requirements. TNL project manager will provide Customer a complete project timeline upon completion of the Project Charter.
Estimated Timeline. Any timelines are only estimates. The timing of completion depends on the actual start date of the project and Customer’s timely completion of its responsibilities set out in this SOW.
Estimated Timeline. As discussed in the conference call on September 11, 2008, this process should begin upon the execution of the signed agreement. As a result of the upcoming elections, we recommend this phase start and be completed within two weeks after contract approval. A notional timeline and project plan is attached. These tasks are primarily offsite task. ● SouthTech integration with Extract to create new GUI user interface screens ● Create an import program for indexing and redaction - develop business rules ● County to identify data elements to be indexed ● Development process (estimated duration: 35 days) ● Completed import of images history ● Completed guidelines document ● Approved business rules development ● County has received hardware, and installed with operating system on network Phase Two will be approximately 5 weeks long. During this phase, the primary task to be completed is the rule writing process, and will require minimal involvement from the County as they prepare for the upcoming elections.
Estimated Timeline. At-scale validation is anticipated to start in December 2012
Estimated Timeline. At-scale validation is anticipated to start in December 2012 • Adherence to timeline and deliverables will be managed per the terms outlined in the Commercial Supply Agreement (CSA) • CMC will provide a weekly timeline update to Inspiration. This will include an update for the tasks for percent completion, actual start dates and actual/target dates for completion • The timeline for activities supporting at-scale validation, including bench scale model qualification, bench scale characterization, viral clearance, resin lifetime validation, and stability validation will need finalization. This work will need to be prioritized against other deliverables associated with the MAA and BLA filings. CMC and Inspiration will prioritize and finalize the timing for these activities after signature of this amendment. The target date for completing the prioritization is 14 days after signature of the amendment • The attached timeline assumes that the Validation campaign will occur in Line A and occur in manufacturing slots already reserved by Inspiration. Inspiration has requested evaluation of an option for two Inspiration manufacturing batches scheduled in Line B in the December 2012 to January 2013 timeframe be eliminated so as to execute batches only in Line A. This would provide the ability to compress the timing for the Process Validation/manufacturing batches in Line A and thus enables a more timely completion of the Process Validation batches and subsequent reports. Such a change would have financial considerations as well as implications for the Line B validation and approval plans. These implications and considerations are not subject of this amendment and will need to be resolved per the terms of the relevant amendments and the CSA. The timeline compression options will be evaluated and agreed to by both parties after signature of this amendment. The target date for completing this agreement is 14 days after signature of the amendment • The attached timeline for Validation is based on the process knowledge known to-date. Delays (due to contract negotiations, delay in the re-start of the HCP reduction work, technical challenges, or change in plans for the process to be implemented) will impact the proposed timeline [**] Stage 1 Bench scale development, optimization and characterization of a new process operation • [**]% payable upon initiation of Stage • [**]% payable upon completion of Stage [**] Stage 2 Method validation/re-validation to support new in-proce...
Estimated Timeline. CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Estimated Timeline. Exhibit G (Construction Timeline) is attached hereto and sets forth the estimated schedule for construction events and the projected dates for the access and expansion dates described above. Such timeline represents the parties current expectations and the parties shall use commercially reasonable efforts to adhere to such projected timeline; provided however (i) in the event of any conflict between the dates in Exhibit G and the time periods required by the body of the Lease, the body of the Lease shall control, and (ii) in no event shall Tenant to entitled to any remedies in the event any of the dates in the projected timeline are not met, unless and to the extent specifically set forth in Section 12 below.
Estimated Timeline. It is anticipated that the likely project will be an optimization of a XOMA [...***...]having an [...***...]using [...***...]This project plan is estimated to require [...***...]months to complete. However, if the [...***...]is greater than [...***...]the timeline is expected to be longer than[...***...]months and would be determined and mutually agreed to following definition of the scope of the alternate program [...***...] BERKELEY, CA and SAN DIEGO, CA – January 6, 2004 – XOMA Ltd. (Nasdaq: XOMA) and Diversa Corporation (Nasdaq: DVSA) today announced that they have entered into a licensing and product development agreement. Under the terms of the agreement, Diversa will receive a license to use XOMA’s antibody expression technology for developing antibody products independently and with collaborators, and an option to a license for the production of antibodies under the XOMA patents. XOMA will receive a license fee and potential future milestone and royalty payments. Under the terms of the development portion of the agreement, XOMA and Diversa will combine their respective capabilities to discover and develop antibodies for autoimmune-related diseases. Diversa will receive research funding and is entitled to receive milestones and royalties on any drugs developed under the agreement. “We are excited to announce this relationship with Diversa,” said Xxxx X. Xxxxxxxx, XOMA’s chairman, president and chief executive officer. “Their ability to generate and optimize antibodies against challenging targets and to improve antibody performance is a valuable capability. XOMA’s bacterial cell expression technology, in turn, is a valuable asset for Diversa’s antibody discovery program.” “We are pleased by this new agreement with XOMA, a company that has demonstrated its ability to successfully develop protein therapeutics and bring them to market,” stated Xxx X. Short, Ph.D., President and Chief Executive Officer of Diversa Corporation. “This advances our pharmaceutical strategy for establishing drug development partnerships in areas other than anti-infectives, which we are focused on developing internally.” Diversa’s Antibody Building System is designed to deliver superior antibodies by generating new antibodies against challenging targets and improving suboptimal antibodies. To create new antibodies, Diversa utilizes its synthetic antibody library of over a billion clones as a basis for generating antibodies against both traditional and refractory targets, as wel...
Estimated Timeline. Milestone Milestone Payment * CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION Estimated Timeline Milestone Milestone Payment
Estimated Timeline. Section Reference Activity Duration
